Sponsor

Chelsea and Westminster NHS Foundation Trust

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Chelsea and Westminster NHS Foundation Trust appears in 26 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials26
Recruiting shown2
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

26 shown
Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy SwitchNCT04892654 · lead sponsor · 2022-08-17
RECRUITING
Effect of Obesity, Diabetes and Bariatric Surgery on Pregnancy OutcomesNCT05753124 · lead sponsor · 2015-05-01
RECRUITING
The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive PatientsNCT05289986 · lead sponsor · 2023-11-21
TERMINATED
Physiological and Environmental Data in a Remote Setting to Predict Exacerbation Events in Patients With Chronic Obstructive Pulmonary DiseaseNCT06118632 · lead sponsor · 2023-09-22
TERMINATED
Efficacy, Tolerability and Acceptability of Biktarvy by TPLWHNCT04944654 · lead sponsor · 2023-01-07
TERMINATED
The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy VolunteersNCT04950530 · lead sponsor · 2022-12-22
COMPLETED
The Effect of Dolutegravir on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy VolunteersNCT04771754 · lead sponsor · 2022-03-20
COMPLETED
Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'NCT04653194 · lead sponsor · 2020-09-30
COMPLETED
Trans People Living With HIV Throughout EuropeNCT03922269 · lead sponsor · 2019-10-11
COMPLETED
Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy VolunteersNCT03894124 · lead sponsor · 2019-06-12
COMPLETED
Aerogen Nebuliser Versus Standard Nebulised Therapy in Acute Chronic Obstructive Pulmonary DiseaseNCT02379065 · lead sponsor · 2015-02-01
COMPLETED
PRIME: Cognitive Outcome Following Major BurnsNCT03242395 · lead sponsor · 2014-10-01
COMPLETED
Bronchoscopic Intrabullous Autologous Blood Instillation (BIABI) for EmphysemaNCT01727037 · lead sponsor · 2012-10-01
UNKNOWN
HIV Indicator Diseases Survey Across Europe - UK ArmNCT01196468 · lead sponsor · 2010-07-01
UNKNOWN
HIV Testing in Non-traditional Settings StudyNCT01138878 · lead sponsor · 2009-07-01
COMPLETED
Biomarkers for Post-treatment Control in HIV: International Study of the EU2Cure Research Consortium (Phase I)NCT07692295 · collaborator · 2026-10-01
NOT_YET_RECRUITING
Exploring a Digital HIV Onward Disclosure Intervention, in People Living With HIV of Sub-Saharan African Ethnicity.NCT05804968 · collaborator · 2023-07-01
UNKNOWN
A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected AdultsNCT04844775 · collaborator · 2022-08-05
COMPLETED
Implementing Long-Acting Novel AntiretroviralsNCT05294159 · collaborator · 2022-07-18
COMPLETED
A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02)NCT04120415 · collaborator · 2022-06-21
COMPLETED
OPEN Feasibility StudyNCT03584412 · collaborator · 2018-07-09
UNKNOWN
Genetic Determinants of Kidney Disease in People of African Ancestry With HIVNCT05685810 · collaborator · 2018-05-01
ACTIVE_NOT_RECRUITING
OPEN Study: Pain Management Treatment Needs InterviewsNCT02972606 · collaborator · 2016-11-01
COMPLETED
Research In Viral Eradication of HIV ReservoirsNCT02336074 · collaborator · 2015-11-27
COMPLETED
The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)NCT01271894 · collaborator · 2011-09-01
COMPLETED
HIV Reverse Cholesterol Transport StudyNCT01670968 · collaborator · 2009-09-01
UNKNOWN

Drugs studied in this sponsor's trials

9 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Chelsea and Westminster NHS Foundation Trust as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
bictegravir 50 MG / emtricitabine 200 MG / tenofovir alafenamide 25 MG Oral Tablet [Biktarvy]2
dolutegravir2
doravirine2
Biktarvy1
doravirine 100 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Delstrigo]1
efavirenz1
raltegravir1
Symtuza1
bictegravir 50 MG / emtricitabine 200 MG / tenofovir alafenamide 25 MG Oral Tablet [Biktarvy] RxCUI 1999673 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials dolutegravir RxCUI 1433868 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 2 trials doravirine RxCUI 2055755 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 2 trials Biktarvy RxCUI 1999668 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial doravirine 100 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Delstrigo] RxCUI 2055815 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial efavirenz RxCUI 195085 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial raltegravir RxCUI 719872 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial Symtuza RxCUI 2049672 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial vorinostat RxCUI 194337 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor15
collaborator11
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.